Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Non-Current Liabilities (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $197000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed 0.0% to $197000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $197000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $197000.0 for FY2025, 0.0% changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $197000.0 at Fulcrum Therapeutics, roughly flat from $197000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $447000.0 in Q2 2023, with the low at $197000.0 in Q2 2022.
  • Average Other Non-Current Liabilities over 4 years is $221866.7, with a median of $197000.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities soared 126.9% in 2023, then tumbled 55.93% in 2024.
  • Over 4 years, Other Non-Current Liabilities stood at $197000.0 in 2022, then changed by 0.0% to $197000.0 in 2023, then changed by 0.0% to $197000.0 in 2024, then changed by 0.0% to $197000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $197000.0, $197000.0, and $197000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.